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Abstract
Purpose: Non-adherence to secondary preventative medications after stroke is relatively common and associated with
poorer outcomes. Non-adherence can be due to a number of patient, disease, medication or institutional factors. The
aim of this review was to identify factors associated with non-adherence after stroke.
Method: We performed a systematic review and meta-analysis of studies reporting factors associated with medication
adherence after stroke. We searched MEDLINE, EMBASE, CINAHL, PsycINFO, CENTRAL and Web of Knowledge. We
followed PRISMA guidance. We assessed risk of bias of included studies using a pre-specified tool based on Cochrane guidance
and the Newcastle–Ottawa scales. Where data allowed, we evaluated summary prevalence of non-adherence and association
of factors commonly reported with medication adherence in included studies using random-effects model meta-analysis.
Findings: From 12,237 titles, we included 29 studies in our review. These included 69,137 patients. The majority of
included studies (27/29) were considered to be at high risk of bias mainly due to performance bias. Non-adherence rate
to secondary preventative medication reported by included studies was 30.9% (95% CI 26.8%–35.3%). Although many
factors were reported as related to adherence in individual studies, on meta-analysis, absent history of atrial fibrillation
(OR 1.02, 95% CI 0.72–1.5), disability (OR 1.27, 95% CI 0.93–1.72), polypharmacy (OR 1.29, 95% CI 0.9–1.9) and age
(OR 1.04, 95% CI 0.96–1.14) were not associated with adherence.
Discussion: This review identified many factors related to adherence to preventative medications after stroke of which
many are modifiable. Commonly reported factors included concerns about treatment, lack of support with medication
intake, polypharmacy, increased disability and having more severe stroke.
Conclusion: Understanding factors associated with medication taking could inform strategies to improve adherence.
Further research should assess whether interventions to promote adherence also improve outcomes.
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Introduction
It is recognised that adherence to secondary preventa-
tive medications after stroke is variable; in some studies
more than half of participants stopped taking their
prescribed drugs 1–2 years after the stroke incident.1–3
Use of the secondary prevention strategies has been
reported to result in 80% reduction in the risk of
stroke recurrence, vascular events or death4,5 and
poor adherence is related to adverse outcomes.6–8
Many factors interfere with the ability of stroke
patients to regularly take their medications. Stroke sur-
vivors may have disability or cognitive issues which
make them unable to self-administer medication.9–11
Personal beliefs and preferences may also impact adher-
ence.10 Medication factors also affect adherence. Drugs
such as anti-coagulants typically have less adherence
than anti-platelets11 and cost of medications is also of
potential importance.9 Health care system failure exists
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through lack of access to health care and inadequate
communication with health care providers.12
Several studies have attempted to identify barriers to
adherence to medication after stroke. Patients with
stroke expressed that concerns about prescribed medi-
cation and unawareness of the rationale of treatment as
primary reasons for non-adherence.13 We performed a
systematic review and meta-analysis of studies that
assessed predictive factors for adherence to preventa-
tive medications in patients with stroke or transient
ischaemic attack (TIA).
Methodology
We performed a systematic review and meta-analysis
following Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) guidelines14
for design, conduct and reporting. The review protocol
was registered in PROSPERO (registration number:
CRD42015027531).
Search strategy and study selection
We generated search strings based on concepts of
‘Stroke’ and ‘Medication Adherence.’ We focussed on
MeSH terms and other controlled vocabulary (avail-
able in the supplementary appendix, which can be
found online with this review). Two independent
reviewers (SA and WD) searched Web of Knowledge,
EMBASE, MEDLINE (both using Ovid), CINAHL,
PsycINFO (both in EBSCOhost) and CENTRAL
(Cochrane Library). Initially, titles were reviewed and
possibly eligible articles were listed for abstract review.
These were then retrieved for entire text review by SA.
We also reviewed reference lists of included studies and
related reviews to detect additional reports.
Eligibility criteria
We only included studies published in English. Studies
had to include adults (aged 18 years) who had suffered
stroke or TIA and were prescribed medication for the
prevention of recurrent cardiovascular events. Studies
had to assess factor(s) that influenced medication adher-
ence. Where disagreement arose regarding study eligibil-
ity, a consensus meeting was arranged with an arbitrator
(JD). We excluded from this review studies that did
not include a measure of medication adherence, studies
that assessed non-pharmacological preventative strate-
gies only or did not include stroke or TIA patients.
Data extraction
We designed a data extraction form that summarised
information on study characteristics, inclusion criteria,
sample size, secondary preventative medications,
method used to measure adherence and predictive fac-
tors. We did not contact the study authors for missing
information or for clarification.
Assessment of risk of bias in included studies
We assessed risk of bias in included studies using a pre-
specified tool generated using Cochrane Library tool
for assessing risk of bias15 and the Newcastle–Ottawa
scales.16 Two independent reviewers (SA and JD)
assessed risk of bias and met to finalise the assessment.
Disagreement was resolved via discussion until reach-
ing a mutual agreement. We considered studies as of
high quality if they met the criteria for all the assess-
ment domains (selection, performance, attrition,
reporting and confounders).
Data synthesis and analysis
We categorised preventative medications as anti-coagu-
lants, anti-platelet, blood pressure or lipid lowering
drugs. Some studies also reported adherence to the
overall medication regimen without specification of
medication classes. We listed predictive factors, signifi-
cance (odds or hazard ratios and 95% confidence inter-
vals) and the type of analysis used. We used the World
Health Organization (WHO) classification of predictive
factors of non-adherence, which categorised these into
five domains:17
– Patient related factors
– Social and economic related factors
– Therapy-related factors
– Health system or health care team related factors
and
– Condition (stroke)-related factors
We described included studies and factors reported
to be significant using a narrative review. Where a
factor was assessed in more than three studies we
described a summary value using random-effects
models meta-analyses. We also described summary
measures of medication non-adherence across
non-case control studies. These analyses used
Comprehensive Meta-Analysis software (CMA, version
2.0, Biostat Inc).
Results
The search was completed in April 2014 and identified a
total of 12,237 titles. Title review identified 143 papers
for abstract review. Of these 57 were retrieved for full-
text review. We identified 29 of these as meeting our
eligibility criteria (Figure 1).1,2,9–12,18–40
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Risk of bias across included studies
Studies included in this review were all of high risk of
bias (except two34,36) mainly because details on per-
formance bias, represented by blinding of outcome
assessor, were not reported. It was also unclear
whether there was a selective reporting of the outcomes
in a study.23 Twelve studies were non-con-
trolled.2,9,10,18–20,22,28,32,38–40 In addition, most studies
used a subjective method to monitor adherence which
has been reported to overestimate patients’ adher-
ence.41,42 More details on other sources of bias in
included studies are available in the supplementary
appendix.
Narrative review
Description of eligible studies. The 29 included studies were
observational studies of which 14 were prospect-
ive cohorts,1,2,9,10,18,20,24,26,32,35,36,38–40 4 were retro-
spective cohorts,22,28,33,34 9 used a cross-sectional
design11,12,21,25,27,29–31,37 and two performed a case-
control analysis.19,23 Details of study characteristics
can be found in Table 1. The total number of partici-
pants in the included studies was 69,137. Reported non-
adherence rate ranged between 11.3%39 and 45.2%.30
Description of predictive factors for non-adherence. Two stu-
dies showed no difference in predictors within groups.
Figure 1. PRISMA flow diagram.
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Table 1. Characteristics of included studies.
Study Design Inclusion criteria Exclusion criteria
Sample
size
Medication
classes
Adherence
assessment
measure
Arif et al.21 Cross-sectional First-time stroke MI
Non-ischaemic or
non-haemorrhagic
TIA
298 AP
AH
LLD
Telephone
interview
Burke et al.22 Retrospective
cohort
First-time IS Previous cardiac
condition
Previous AT
1413 AP Prescription
refill
Bushnell et al.18 Observational
cohort,
3 months
IS or TIA – 2598 AP
AC
AH
LLD
Telephone
interview
Bushnell et al.18 Longitudinal
study, 1 year
IS or TIA – 2457 AP
AC
AH
LLD
Telephone
interview
Chambers et al.23 Case-control
study
First- time IS Institutional living 26 Not
specified
MARS and
BMQ
Choi-Kwon
et al.24
Observational
cohort,
1–5 years
Early-onset stroke
patients (onset
between ages
of 15–45 years)
HS
TIA
Severe medical
conditions
Previous stroke
256 AH Patient
interview
Coetzee et al.25 Cross-sectional
at 6 weeks
Completed
rehabilitation program
– 26 (compared
to 29 amputee
patients)
All classes Patient
interview
and pill
count
De Schryver
et al.26
Cohort study,
1–2 years
Patients in the Dutch
TIA Trial and the
Stroke Prevention
In Reversible
Ischaemia Trial
– 3796 (aspirin)
and 651 (AC)
Aspirin
AC
Patient
interview
and pill
count
Edmondson
et al.27
Cross-sectional Age> 40 years
Stroke or TIA
Institutional living
Pregnant
Aphasia
Cognitive
impairment
535 AT
AH
LLD
MMAS and
BMQ
Glader et al.2 Prospective
observational
study, 2 year
Patients in the
Swedish Stroke
Register
– 24,024 AP
AC
AH
LLD
Prescription
refill
Huang et al.28 Retrospective
cohort, 1 year
IS or TIA In-hospital stroke 11,050 AT
AH
LLD
Prescription
refill
Ji et al.29 Cross-sectional,
at 3 months
IS or TIA – 9998 AP
AC
AH
LLD
Telephone
interview
Ke et al.30 Cross-sectional Cerebral infarction
TIA
– 1240 Aspirin Telephone
interview
(continued)
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Table 1. Continued
Study Design Inclusion criteria Exclusion criteria
Sample
size
Medication
classes
Adherence
assessment
measure
Kronish et al.31 Cross-sectional Stroke or TIA
in the past 5 years
Institutional living
Pregnant
Aphasia
Cognitive
impairment
535 Not
specified
MMAS
Kronish et al.12 Cross-sectional
study
Stroke or TIA
Age 40 years
Aphasia
Cognitive
impairment
Pregnant
Institutional
living
600 Not
specified
MMAS
Levine et al.19 Case-control
study
Stroke
Age 45 years
Noninstitutionalized
– 8673 Not
specified
Questionnaire
Lopes et al.32 Longitudinal
study, 1 year
IS or TIA with AF
in Get With
The Guidelines
(GWTG)–Stroke
registry & Adherence
eValuation After
Ischemic Stroke
Longitudinal (AVAIL)
registry
Bleeding
Palliative-care
Death or
transfer from
hospital
291 AC Patient
interview
Lummis et al.9 Cohort study,
1 year
Stroke patients in
the Stroke Outcome
Study
– 420 AT
AH
LLD
Self-reported
adherence
O’Carroll et al.10 Longitudinal
study, 1 year
First-time IS
Responsible for
own medication
Institutional
living
180 AH
Aspirin
LLD
MARS,
BMQ and
urinary-
salicylate
level
Østergaard et al.33 Retrospective
cohort
Suspected stroke HS 503 AP Prescription
refill
Østergaard et al.34 Retrospective
cohort,
1.7 years
TIA Prior TIA or
stroke &
previous AC
594 AP Prescription
refill
Rodriguez et al.35 Longitudinal
study, 1 year
IS or TIA
GWTG-Stroke
program
– 2720 AP
AC
AH
LLD
Telephone
interview
Sappok et al.36 Prospective
observational
study, 1 year
IS or TIA Haemorrhage
Migraine
Epilepsy
470 AT Telephone
interview
Sjo¨lander et al.38 Prospective
observational
study
Ischemic stroke
in the Swedish
Stroke Register
– 18,349 AH Medication
refill
Sjo¨lander et al.37 Cross-sectional Stroke Institutional-living 578 Not
specified
MARS
Thrift et al.20 Prospective
cohort,
10 years
Stroke Subarachnoid
haemorrhage
1241 AT
AH
LLD
Self-reported
adherence
(continued)
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One compared factors between rural and urban resi-
dence35 and the other compared patients living in
different income quintiles.28 Factors related to non-
adherence in the other 27 studies are classified below
and detailed in the supplementary appendix.
Patient-related factors. Younger age at time of stroke
was associated with reduced medication adherence in
seven studies9,10,18,24,26,33,34 whereas younger age
reported to associate with better adherence in five stu-
dies.2,29,36,39,40 Three studies reported that female sex
predicted decreased adherence2,29,32 whereas one
reported the opposite.37
Other patient-related factors included having con-
cerns about medication, which associated with
decreased adherence in four studies,10,12,27,30 or when
patients perceived no benefit of treatment as reported in
one study.10 On the other hand, when patients had
positive beliefs about medication23,25,37 and indicated
they were aware of the consequence of not taking pre-
scribed medication,23 these factors were associated with
enhanced adherence to medication.
Socioeconomic factors. Three studies indicated that
having some sort of education21,40 or settled work
status18 were associated with improved adherence.
Four studies reported that the presence of patient
carer or supporter also predicted better adher-
ence.2,23,25,29 Two studies reported that living at care
institution other than home was associated with wor-
sened adherence.2,39
Therapy-related factors. Disease- or health-related
factors that predicted non-adherence included dis-
ability,1,9,18,29,37,39 reduced cognition function,10,23,25,37
poor quality of life2,11,18 and low mood.2,25 Smoking9,34
and alcohol consumption34,40 were also predictors of
medication non-adherence.
Existence of co-morbidities at the time of stroke
associated with improved adherence to treatment.
These included history of hypertension,18,29,34 dia-
betes,2,18 dyslipidaemia,18,21,40 coronary artery dis-
ease18,40 or myocardial infarction.18,33 Conversely, the
absent history of atrial fibrillation was associated with
better adherence.2,18,29,36,40
Prescribed regimen factors that predicted enhanced
adherence included understanding of medication
rationale,1,18,23,30 awareness of duration of treatment,30
knowledge of how to refill prescription,18 previous
treatment by the same medication class,2,38,40 prescrip-
tion and education at hospital discharge after the inci-
dent.20 Also, development of medication routine23 and
use of compliance aid by patient.1
Medication regimen factors which associated with
reduced adherence included cost of medication9,19,22
and number and frequency of prescribed drugs.1,9,18,29
Health system or caregiver-related factors. Caregiver-
related factors included prescriber speciality (e.g. neur-
ologist).1 Patient–caregiver relationship factors
included language barrier, low trust, perceived discrim-
ination, inadequate continuity of care1 and inadequate
communication of information regarding prescribed
regimen.30
Institution factors associated with better adherence
included treating facility i.e. treated in stroke unit,2,37
treated in academic hospital29 and hospital size.18
Additionally, arrangement of medical insurance11,24
and accessible health care facility2,12 predicted
enhanced adherence.
Stroke-related factors. Stroke-related factors that
predicted non-adherence included delay from onset of
symptoms to evaluation,34 symptoms of post-traumatic
stress disorder (PTSD),27,31 more severe stroke,33,36,39,40
previous stroke incidence2,9,37 and time from stroke
Table 1. Continued
Study Design Inclusion criteria Exclusion criteria
Sample
size
Medication
classes
Adherence
assessment
measure
Wang et al.11 Cross-sectional,
at 1 year
TIA or a
cerebral infarction
Haemorrhage
Migraine
Epilepsy
722 AT Telephone
interview
Weimar et al.39 Observational
cohort,
1–2 years
Cerebrovascular
disease with AF
Intracerebral
haemorrhage
293 AC Patient
interview
Xu et al.40 Prospective
cohort, 1-year
Stroke
Hypertension
– 7880 AH Telephone
interview
AC: anti-coagulants; AF: atrial fibrillation; AH: anti-hypertensives; AP: anti-platelets; AT: anti-thrombotics; BMQ: beliefs about medicines questionnaire;
HS: haemorrhagic stroke; IS: ischaemic stroke; LLD: lipid-lowering drugs; MARS: medication adherence report scale; MMAS: Morisky-medication
adherence scale.
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onset.27 Stroke subtype was another predictor of non-
adherence e.g. ischaemic stroke versus Tia,29 cardio-
embolic36 and haemorrhagic stroke.2 Nevertheless,
factors like reduced cognition, disability and poor
quality of life could also be stroke-related.
Meta-analysis
Sixteen studies were eligible for the meta-analysis
of prevalence of non-adherence as they provided
a measure of medication non-adherence
rate.1,11,20–22,26,27,29–31,33–35,37,39,40 The rate of non-
adherence was 30.9% (95% CI 26.8–35.3%) (Figure 2).
For the meta-analysis of effect of factors on medica-
tion adherence, four factors were eligible which were:
absent history of AF (4 studies2,18,29,36), disability
(5 studies1,9,18,29,39), polypharmacy (4 studies1,9,18,29)
and age of the patient (7 studies2,9,18,29,36,39,40). Meta-
analyses of these factors showed that these factors did
not significantly associate with medication adherence
(no AF OR 1.02, 95% CI 0.72–1.5 (p¼ 0.9); disability
OR 1.27, 95% CI 0.93–1.72 (p¼ 0.13); polypharmacy
OR 1.29, 95% CI 0.9–1.9 (p¼ 0.17); age OR 1.04, 95%
CI 0.96–1.14 (p¼ 0.34)). Forest plots for each factor
analysis are available in Figure 3. There was consider-
able heterogeneity across all studies included in the
meta-analyses (all I2> 88%).
Discussion
In this review, we identified factors associated with
adherence behaviour to secondary preventative medica-
tion after stroke or TIA. As stated by the WHO,
patients alone used to be held responsible for non-
adherence; however, it has been identified that other
factors including the health care system or providers
can also impact on non-adherence.17
Many factors associated with enhanced adherence to
secondary preventative medication including positive
beliefs about medication.23,25,37 This also included
patients who encountered lower cost of medica-
tions9,19,22 or had medical insurance.11,24
Most of the published work focusses on patient and
drug specific factors as determinants of adherence. The
importance of institution or health care factors should
not be neglected. Prescribing and educating patients on
medication for secondary prevention before hospital
discharge was linked to improved adherence.20
Figure 2. Meta-analysis of prevalence of non-adherence within included studies.
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Figure 3. Meta-analyses of predictive factors.
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Numerous studies showed that in-hospital initiation of
secondary preventative medication resulted in higher
rates of adherence.20,43,44 This should include details on
the purpose of treatment and regimen dosage.1,18,23,30
Also, patients should be ensured adequate continuity
of care1 and access to health care after stroke.2,12
These simple measures could improve clinical
outcomes.
Nonetheless, stroke patients with disability,1,9,18,29,37,39
reduced cognitive function,10,23,25,37 increased number
of prescribed medication,1,9,18,29 concerns about treat-
ment,10,12,27,30 history of stroke2,9,37 or more severe
stroke event33,36,39,40 commonly showed reduced adher-
ence to treatment.
Factors reported in this review were similar to those
reported to correlate with adherence to medication in
cardiovascular disease including coronary heart disease
and acute coronary syndrome45–48 and to medications
in general.49,50
Two patient-related factors were controversial in pre-
dicting adherence to secondary preventative medication,
age at the time of stroke incident2,9,10,18,24,29,33,34,36,39,40
and sex of the patient.2,29,32,37 A study that assessed dif-
ferences in prescribing secondary preventative drugs to
stroke patients found significant differences where
women were less likely to receive all recommended sec-
ondary preventative medication classes than men.
However, younger patients were less likely to receive
anti-platelet treatment.51 These factors are, however,
non-reversible or amendable thus health care practi-
tioners need to not hesitate with secondary prevention
therapy if prescribing does not contrast with evidence-
based recommendations.
In the meta-analysis of prevalence of non-adherence,
we found non-adherence to be high with almost a third
of stroke patients not receiving adequate secondary
prevention. This clearly indicates importance for apply-
ing interventions that would improve adherence espe-
cially in the group vulnerable for non-adherence.
Despite the fact that none of the factors meta-
analysed in this review showed significant association
with medication adherence, caution should be taken
not to interpret that association does not exist. This is
explainable by the heterogeneity within included studies
which was due to the considerable variation in sub-
jects’ inclusion criteria, factors reported, medication
classes, definition of adherence or compliance and the
analysis used.
Limitations
There were several limitations of this review. Available
data are heterogeneous as a result of lack of universal
reporting of medication adherence. In addition, there
was no standardised scale to critically appraise type of
included studies. Also, inclusion and exclusion specifi-
cation could have influenced reporting predictors e.g. if
a study excluded participants of specific age or popula-
tion who are known to have a high risk of non-
adherence.
Implication for practice and
future research
In this review, we aimed to identify factors correlated
with adherence to secondary preventative medication
after stroke. When clinicians are able to discuss barriers
of adherence with their patients, they could ensure
reducing the burden of treatment on their patients. It
is also essential to identify reversible factors, e.g. mis-
beliefs or complex regimens, as these can be addressed.
On the other hand, knowing factors that encourage
stroke patients to adhere, clinicians would also be
able to support stroke patients who are already adher-
ing to maintain a good level of adherence. Researchers
need to identify which interventions work best in sup-
porting stroke patients to safely continue treatment
with secondary preventative medication. Also, meas-
ures for detecting and tackling difficulties for medica-
tion administration after stroke need to be tested and
implemented.
Conclusion
Potential stroke patients with identified factors that
predicted non-adherence require further attention, con-
tinuous encouragement and support with medication
intake. Factors frequently reported to affect adherence
included concerns about treatment regimen, increased
disability, suffering severe stroke, polypharmacy and
complex medication regimen. Focus should be more
on reversible factors such as correcting misbeliefs
about medication and providing convenient regimen.
Stroke patients with disability or reduced cognition
should be given additional care.
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